BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho
PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Barry Ticho to its Scientific Advisory Board effective December 1, 2024. Dr. Ticho brings over 25 years of biopharma and drug development expertise, currently serving as Chief Medical Officer at Stoke Therapeutics. His experience includes co-founding Verve Therapeutics and leading R&D initiatives at Moderna Therapeutics, Pfizer, and Biogen.
Dr. Ticho has notably transformed Stoke from a 9-employee private company to a publicly traded organization with over 100 employees, focusing on genetic diseases in neurology and ophthalmology. He holds an MD and PhD from the University of Chicago and serves on multiple Scientific Advisory Boards including Cardior Pharmaceuticals, Mana.bio, and Sania.
La sussidiaria di PreveCeutical Medical, BioGene Therapeutics, ha nominato il Dr. Barry Ticho nel suo Consiglio Scientifico, con effetto dal 1 dicembre 2024. Il Dr. Ticho porta con sé oltre 25 anni di esperienza nel settore biopharma e nello sviluppo di farmaci, attualmente ricoprendo il ruolo di Chief Medical Officer presso Stoke Therapeutics. La sua esperienza include la co-fondazione di Verve Therapeutics e la guida di iniziative di R&D presso Moderna Therapeutics, Pfizer e Biogen.
Il Dr. Ticho ha notevolmente trasformato Stoke da una compagnia privata con 9 dipendenti a un'organizzazione quotata in borsa con oltre 100 dipendenti, concentrandosi su malattie genetiche in neurologia e oftalmologia. Ha conseguito un MD e un PhD presso l'Università di Chicago e fa parte di diversi Consigli Scientifici, tra cui Cardior Pharmaceuticals, Mana.bio e Sania.
La subsidiaria de PreveCeutical Medical, BioGene Therapeutics, ha nombrado al Dr. Barry Ticho en su Consejo Asesor Científico, con efecto a partir del 1 de diciembre de 2024. El Dr. Ticho aporta más de 25 años de experiencia en biopharma y desarrollo de medicamentos, actualmente desempeñándose como Director Médico en Stoke Therapeutics. Su experiencia incluye la cofundación de Verve Therapeutics y la dirección de iniciativas de I+D en Moderna Therapeutics, Pfizer y Biogen.
El Dr. Ticho ha transformado notablemente Stoke de una empresa privada de 9 empleados a una organización que cotiza en bolsa con más de 100 empleados, centrándose en enfermedades genéticas en neurología y oftalmología. Tiene un MD y un PhD de la Universidad de Chicago y forma parte de varios Consejos Asesores Científicos, incluyendo Cardior Pharmaceuticals, Mana.bio y Sania.
프리브시유티컬 메디컬의 자회사인 BioGene Therapeutics가 배리 티코 박사를 2024년 12월 1일부터 과학 자문위원회에 임명했습니다. 티코 박사는 생명공학 및 의약품 개발 분야에서 25년 이상의 경험을 가지고 있으며, 현재 스톡 테라퓨틱스의 최고 의학 책임자로 활동하고 있습니다. 그의 전문 경력에는 Verve Therapeutics의 공동 설립과 Moderna Therapeutics, Pfizer, Biogen에서의 연구 개발(R&D) 이니셔티브 리딩이 포함됩니다.
티코 박사는 스톡을 9명의 직원으로 구성된 비공식 회사에서 100명 이상의 직원이 있는 상장 회사로 변모시키는 데 크게 기여했습니다. 그는 신경학 및 안과의 유전 질환에 중점을 두고 있습니다. 그는 시카고 대학교에서 MD와 PhD를 취득했으며, Cardior Pharmaceuticals, Mana.bio 및 Sania를 포함한 여러 과학 자문위원회에서 활동하고 있습니다.
La filiale de PreveCeutical Medical, BioGene Therapeutics, a nommé le Dr Barry Ticho au sein de son Conseil Consultatif Scientifique, à compter du 1er décembre 2024. Le Dr Ticho apporte plus de 25 ans d'expertise en biopharmaceutique et en développement de médicaments, occupant actuellement le poste de directeur médical chez Stoke Therapeutics. Son expérience comprend la co-fondation de Verve Therapeutics et la direction d'initiatives de R&D chez Moderna Therapeutics, Pfizer et Biogen.
Le Dr Ticho a notamment transformé Stoke d'une entreprise privée de 9 employés en une organisation cotée en bourse comptant plus de 100 employés, axée sur les maladies génétiques en neurologie et en ophtalmologie. Il possède un MD et un PhD de l'Université de Chicago et siège à plusieurs Conseils Consultatifs Scientifiques, notamment chez Cardior Pharmaceuticals, Mana.bio et Sania.
Die Tochtergesellschaft von PreveCeutical Medical, BioGene Therapeutics, hat Dr. Barry Ticho mit Wirkung zum 1. Dezember 2024 in seinen Wissenschaftlichen Beirat berufen. Dr. Ticho bringt über 25 Jahre Erfahrung in der Biopharma- und Arzneimittelentwicklung mit und ist derzeit Chief Medical Officer bei Stoke Therapeutics. Zu seinen Erfahrungen gehört die Mitbegründung von Verve Therapeutics und die Leitung von F&E-Initiativen bei Moderna Therapeutics, Pfizer und Biogen.
Dr. Ticho hat Stoke von einem privaten Unternehmen mit 9 Mitarbeitern zu einer börsennotierten Organisation mit über 100 Mitarbeitern transformiert, wobei der Fokus auf genetischen Krankheiten in der Neurologie und Augenheilkunde liegt. Er hat einen MD und einen PhD von der University of Chicago und ist Mitglied mehrerer Wissenschaftlicher Beiräte, darunter Cardior Pharmaceuticals, Mana.bio und Sania.
- Appointment of highly experienced industry veteran with 25+ years in biopharma and drug development
- Strategic addition of expertise in neurology, ophthalmology, cardiovascular, and metabolic diseases
- Access to extensive network through appointee's connections with major pharmaceutical companies (Pfizer, Moderna, Biogen)
- None.
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Barry Ticho M.D. Ph.D to the Scientific Advisory Board effective on 1 December, 2024.
Stephen Van Deventer, CEO of BioGene, commented:
"We are honored to welcome Dr. Barry Ticho M.D.Ph.D to our Scientific Advisory Board. Barry's extensive leadership in drug development and biopharma, coupled with his entrepreneurial spirit, will bring unparalleled insight to BioGene's mission to deliver innovative therapies. His deep expertise in advancing groundbreaking treatments across neurology, ophthalmology, cardiovascular, and metabolic diseases perfectly aligns with our focus areas, and we look forward to his contributions to our scientific and strategic initiatives."
Dr. Barry Ticho's Career Highlights:
Dr. Ticho is a physician-scientist and entrepreneur with over 25 years of biopharma and drug development expertise. Currently serving as Chief Medical Officer at Stoke Therapeutics (NASDAQ: STOK), Dr. Ticho has played a pivotal role in transforming Stoke from a private company with nine employees to a publicly traded organization with more than 100 employees and clinical programs targeting severe genetic diseases in neurology and ophthalmology.
Dr. Ticho also co-founded Verve Therapeutics and served as its first CEO, pioneering a novel gene-editing approach to prevent cardiovascular disease. Under his leadership, Verve Therapeutics laid the foundation for its public offering in 2021 (NASDAQ: VERV). Prior to these roles, Dr. Ticho led R&D initiatives for Cardiovascular and Metabolic Diseases at Moderna Therapeutics, and he has held senior leadership positions at Pfizer and Biogen, where he directed groundbreaking programs in heart failure, multiple sclerosis, and Alzheimer's disease.
Dr. Ticho's academic and advisory contributions are equally impressive. He serves on the Scientific Advisory Boards for Cardior Pharmaceuticals, Mana.bio, and Sania, as well as the Board of Advisors for the Museum of Science in Boston, where he champions science education and community outreach. A passionate advocate for science and innovation, Dr. Ticho has inspired new generations of scientists through his work.
Dr. Ticho earned his MD and PhD from the University of Chicago and completed his Pediatrics training at Northwestern University, followed by a Cardiology fellowship at Boston Children's Hospital. He has also held clinical staff positions at Harvard Medical School and Massachusetts General Hospital.
Dr. Ticho remarked on his appointment:
"I am delighted to join BioGene's Scientific Advisory Board and collaborate with a team deeply committed to advancing transformative therapies. BioGene's focus on addressing critical unmet medical needs aligns with my professional passion for innovation and patient-centered solutions. I look forward to contributing to the company's exciting future."
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's
On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232415
FAQ
When did Dr. Barry Ticho join PreveCeutical Medical's (PRVCF) Scientific Advisory Board?
What is Dr. Barry Ticho's current role besides his position at PreveCeutical Medical (PRVCF)?
What major pharmaceutical companies has Dr. Barry Ticho worked for before joining PreveCeutical Medical (PRVCF)?
